Curated News
By: NewsRamp Editorial Staff
April 08, 2026
Cardio Diagnostics Partners with IBN to Advance AI-Powered Heart Disease Solutions
TLDR
- Cardio Diagnostics Holdings (NASDAQ: CDIO) partners with IBN to enhance its market position by promoting its AI-driven cardiovascular tests, offering investors a strategic advantage in precision medicine.
- Cardio Diagnostics integrates epigenetics, genetics, and AI into clinical tests like Epi+Gen CHD to analyze molecular biomarkers and generate patient-specific cardiovascular risk assessments.
- Cardio Diagnostics' technology makes cardiovascular disease prevention and detection more accessible and personalized, potentially saving lives and improving public health outcomes globally.
- Cardio Diagnostics uses AI to combine genetics and epigenetics, creating innovative blood tests that predict heart disease risk years in advance.
Impact - Why it Matters
This partnership matters because cardiovascular disease remains the leading cause of death globally, claiming nearly 18 million lives annually. Traditional risk assessment methods often lack precision and accessibility, leaving many at risk undetected until symptoms appear. Cardio Diagnostics' innovative approach combining epigenetics, genetics and artificial intelligence represents a paradigm shift toward personalized, predictive medicine. Their blood-based tests could enable earlier intervention and more targeted prevention strategies, potentially reducing healthcare costs and saving lives. The engagement with IBN's extensive communications network suggests the company is preparing for broader market awareness and adoption, which could accelerate the availability of these advanced diagnostic tools to healthcare providers and patients worldwide.
Summary
Cardio Diagnostics Holdings (NASDAQ: CDIO), a precision cardiovascular medicine company leveraging epigenetics, genetics and artificial intelligence, has engaged IBN to support its corporate communications strategy as it advances blood-based solutions for the prevention and detection of cardiovascular disease. The company develops and commercializes clinical tests and data platforms that integrate molecular biomarkers with AI to generate patient-specific insights, including Epi+Gen CHD™, a prescription-only test for assessing three-year coronary heart disease risk, PrecisionCHD™ for detection and management, HeartRisk™ for population-level intelligence and CardioInnovate360™ to support cardiovascular therapy development.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions.
With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To view the full press release, visit https://ibn.fm/hFqWS. The latest news and updates relating to CDIO are available in the company’s newsroom at https://ibn.fm/CDIO. For more information, please visit https://www.BioMedWire.com. BioMedWire is powered by IBN.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cardio Diagnostics Partners with IBN to Advance AI-Powered Heart Disease Solutions
